Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.
Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-naïve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.
Escudier
Bernard
B
Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France;
Cosaert
Jan
J
Jethwa
Sangeeta
S
BJU Int. 2008 Apr;101(8):949-58
18241251
J Urol. 2006 Dec;176(6 Pt 1):2353-8
17085101
Biochimie. 2007 Jun-Jul;89(6-7):884-93
17532550
J Urol. 2003 Dec;170(6 Pt 1):2163-72
14634372
BJU Int. 2007 May;99(5 Pt B):1282-8
17441925
N Engl J Med. 2003 Jul 31;349(5):419-21
12890838
Br J Cancer. 2003 Jun 16;88(12):1979-86
12799646
Nature. 1993 Apr 29;362(6423):841-4
7683111
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s
17255307
Cancer. 2007 Dec 1;110(11):2468-77
17932908
Lancet. 2007 Dec 22;370(9605):2103-11
18156031
J Clin Oncol. 2007 Oct 10;25(29):4536-41
17876014
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Am J Surg Pathol. 2003 May;27(5):612-24
12717246
Biochem Biophys Res Commun. 1989 Jun 15;161(2):851-8
2735925
Ann Oncol. 2008 Aug;19(8):1470-1476
18408224
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s
17255293
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S
15448032
Cancer Res. 2001 Jul 1;61(13):5090-101
11431346
J Clin Oncol. 2007 Aug 1;25(22):3296-301
17664477
J Clin Oncol. 2007 Aug 1;25(22):3288-95
17664476
J Clin Oncol. 2009 Mar 20;27(9):1432-9
19224847
J Clin Oncol. 2006 Dec 10;24(35):5593-600
17158545
J Clin Oncol. 1999 Sep;17(9):2859-67
10561363
N Engl J Med. 1996 Sep 19;335(12):865-75
8778606
J Exp Med. 1971 Feb 1;133(2):275-88
4332371
J Clin Oncol. 2006 Dec 10;24(35):5576-83
17158543
BJU Int. 2007 May;99(5 Pt B):1223-9
17441915
Clin Genitourin Cancer. 2009 Jan;7(1):24-7
19213664
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Ann Oncol. 2008 Apr;19(4):631-40
18281267
Science. 1983 Feb 25;219(4587):983-5
6823562
J Clin Oncol. 2001 Feb 1;19(3):843-50
11157038
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Oncologist. 2001;6(1):34-55
11161227
Science. 1989 Dec 8;246(4935):1306-9
2479986
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
J Clin Oncol. 2004 Feb 1;22(3):454-63
14752067
J Clin Invest. 1995 Apr;95(4):1789-97
7535799
Cancer Res. 2004 Jun 1;64(11):3731-6
15172975
ScientificWorldJournal. 2007 Apr 09;7:837-49
17619768
Ann Oncol. 2007 Mar;18(3):581-92
17287242
Nat Med. 1998 Mar;4(3):336-40
9500609
Endocr Rev. 2004 Aug;25(4):581-611
15294883
Crit Rev Oncol Hematol. 2007 Dec;64(3):247-62
17662611
N Engl J Med. 1971 Nov 18;285(21):1182-6
4938153
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Nature. 1996 Apr 4;380(6573):435-9
8602241
Lancet. 1999 Jan 2;353(9146):14-7
10023944
Nat Med. 2003 Jun;9(6):669-76
12778165
Nat Med. 2004 Feb;10(2):145-7
14745444
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
15674877
J Clin Invest. 2006 Oct;116(10):2610-21
17016557
Cancer Res. 1997 Oct 15;57(20):4593-9
9377574
Oncology. 2005;69 Suppl 3:4-10
16301830
Cancer Res. 1986 Nov;46(11):5629-32
3756910
Growth Factors. 1992;7(1):53-64
1380254
J Cancer Res Clin Oncol. 1998;124(3-4):141-7
9619739
Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9
12516032
J Clin Oncol. 2003 Jan 1;21(1):60-5
12506171
Eur J Cancer. 2008 Jul;44(10):1345-89
18280139
J Clin Oncol. 2006 Dec 10;24(35):5584-92
17158544
Semin Oncol. 2000 Apr;27(2):187-93
10768597
Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35
15961063
Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38
16153592
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
J Clin Oncol. 2002 Jan 1;20(1):289-96
11773181
J Clin Oncol. 2001 Feb 1;19(3):851-6
11157039
BJU Int. 2004 Feb;93(3):297-302
14764126
Pathology. 2007 Oct;39(5):459-65
17886093
FASEB J. 2000 Dec;14(15):2373-6
11024009
Eur Urol. 2007 Jun;51(6):1502-10
17408850
Nat Med. 1999 Jun;5(6):623-8
10371499